Hematopoietic stem cell transplantation

Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

Retrieved on: 
Thursday, August 29, 2019
Medical specialties, Medicine, Clinical medicine, Hematology, Hematopoietic stem cell transplantation, Lymphology, Surgical oncology, Transplantation medicine

NEW YORK and LONDON, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.

Key Points: 
  • NEW YORK and LONDON, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the second quarter ended June 30, 2019 and recent clinical progress.
  • In addition, we are planning to start a pivotal clinical trial for HSCT-TMA in the fourth quarter of this year.
  • The Company continues to progress towards a pivotal trial for HSCT-TMA with nomacopan, which is expected to start in the fourth quarter of 2019.
  • General and administrative (G&A) expenses in the second quarter of 2019 were $2.4 million, as compared to $2.9 million in the same quarter last year.

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

Retrieved on: 
Wednesday, August 14, 2019
Health, Medicine, Medical specialties, Food and Drug Administration, Fast track, Priority review, Investigational New Drug, Hematopoietic stem cell transplantation, Breakthrough therapy

The Fast Track designation follows a successful pre-investigational new drug (IND) FDA meeting earlier this year regarding Akaris proposed pivotal clinical trial program for HSCT-TMA.

Key Points: 
  • The Fast Track designation follows a successful pre-investigational new drug (IND) FDA meeting earlier this year regarding Akaris proposed pivotal clinical trial program for HSCT-TMA.
  • Proposed pivotal trial of nomacopan in pediatric patients with HSCT-TMA expected to start Q4 2019 in North America and Europe.
  • The Fast Track designation supports Akaris plans for expedited approval of nomacopan for HSCT-TMA, with the pivotal trial expected to commence in the fourth quarter of 2019.
  • Drugs with Fast Track designation may qualify for priority review to expedite the FDA review process, if relevant criteria are met.

City of Hope Now Enrolling Patients for First-in-Human T Cell Trial for HPV-Associated Cancers

Retrieved on: 
Thursday, August 15, 2019
Infectious diseases, General Health, Hospitals, Genetics, Science, Clinical trials, Biotechnology, Health, Other Science, Research, Pharmaceutical, Stem cells, Medicine, Clinical medicine, Health, Cancer treatments, Virotherapy, RTT, Stem cells, Transplantation medicine, Immunotherapy, Hematopoietic stem cell transplantation, Cancer, Therapy

The first-in-human, phase 1 T cell trial for patients who have human papillomavirus (HPV)-associated cancers that have relapsed, or are resistant to treatment, is now open at City of Hope .

Key Points: 
  • The first-in-human, phase 1 T cell trial for patients who have human papillomavirus (HPV)-associated cancers that have relapsed, or are resistant to treatment, is now open at City of Hope .
  • These patients currently have few treatment options so we are hopeful that T cell therapy will work.
  • The trial is part of City of Hopes T Cell Therapeutics Research Laboratory, which currently has 20 T cell and CAR T clinical trials.
  • Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy .

Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications

Retrieved on: 
Thursday, August 15, 2019
Medical specialties, Medicine, Clinical medicine, Mucositis, Hematopoietic stem cell transplantation, Organ transplantation, National Institute of Dental and Craniofacial Research

This award will facilitate the assessment of SGX942 safety in juvenile animals, supporting future studies in pediatric populations, including oral mucositis indications in pediatric patients undergoing stem cell transplants and treatments for head and neck cancer.

Key Points: 
  • This award will facilitate the assessment of SGX942 safety in juvenile animals, supporting future studies in pediatric populations, including oral mucositis indications in pediatric patients undergoing stem cell transplants and treatments for head and neck cancer.
  • "We are appreciative of the continued support provided by NIDCR for the SGX942 development program," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.
  • "We believe this SBIR grant award further validates dusquetide's novel mechanism of action, as well as the positive clinical data generated to date.
  • It can occur in any mucosal region, but is most commonly associated with the mouth, followed by the small intestine.

Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, August 8, 2019
Biotechnology, Health, Stem cells, Pharmaceutical, Medical specialties, Medicine, Color, Stem cells, Magenta, Hematopoietic stem cell transplantation

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the second quarter ended June 30, 2019 and recent business highlights.

Key Points: 
  • Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the second quarter ended June 30, 2019 and recent business highlights.
  • Study enrollment is on track, and Magenta expects to present data from the study in the second half of 2019.
  • Magenta expects to update longer term results in these patients in the second half of 2019.
  • Net Loss: Net loss was $17.7 million for the second quarter of 2019, compared to net loss of $13.7 million for the second quarter of 2018.

Global Cancer Stem Cell Therapeutics Market 2019-2023 | Key Insights and Forecasts | Technavio

Retrieved on: 
Monday, August 5, 2019
Health, Oncology, Stem cells, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Transplantation medicine, Cell biology, Carcinogenesis, Hematopoietic stem cell transplantation, Cancer stem cell, Stem-cell therapy

View the full release here: https://www.businesswire.com/news/home/20190805005279/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190805005279/en/
    Technavio has announced its latest market research report titled global cancer stem cell therapeutics market 2019-2023.
  • In this report, Technavio highlights the availability of stem cell markers as one of the key emerging trends in the global cancer stem cell therapeutics market.
  • Global cancer stem cell therapeutics market: Availability of stem cell markers
    The identification of cancer stem cells is challenging due to the heterogeneity in cervical carcinoma.
  • Global cancer stem cell therapeutics market: Segmentation analysis
    This market research report segments the global cancer stem cell therapeutics market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

Cancer Stem Cell Therapy Market, 2025 - 37 Therapies in Cancer Stem Cell Therapy Clinical Pipeline / 18 Therapies Majority Stem Cells In Preclinical Phase

Retrieved on: 
Wednesday, July 31, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Life extension, Stem-cell therapy, Cell therapy, Cancer stem cell, Therapy, Hematopoietic stem cell transplantation

"Global Cancer Stem Cell Therapy Market, Price, Dosage and Clinical Trial Insight 2025" Report Highlights:

Key Points: 
  • "Global Cancer Stem Cell Therapy Market, Price, Dosage and Clinical Trial Insight 2025" Report Highlights:
    Global Bone Marrow Transplant Market Opportunity: US$ 15 Billion
    Cancer Stem Cell Therapy Clinical Pipeline: 37 Therapies
    Majority Stem Cells In Preclinical Phase: 18 Therapies
    Cancer Stem Cell Therapy Clinical Pipeline by Country: More Than 30 In USA
    Cancer incidences are escalating as a result of which demand for better therapeutics is increasing across the globe.
  • Cancer stem cell therapeutics is expected to change this scenario as they act on the very basis of the development of cancer cells.
  • Innovations in the pharmaceutical industry seem to be the main driving force for the development of cancer stem cell therapies.
  • As a result, large numbers of cancer stem cell therapies are entering clinical trials across the globe.

Global Cancer Stem Cell Therapy Market to 2025 - Price, Dosage and Clinical Trial Insights - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 31, 2019
Health, Oncology, Stem cells, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Life extension, Stem-cell therapy, Cell therapy, Therapy, Hematopoietic stem cell transplantation, Draft:Tissue engineering

"Global Cancer Stem Cell Therapy Market, Price, Dosage and Clinical Trial Insight 2025" Report Highlights:

Key Points: 
  • "Global Cancer Stem Cell Therapy Market, Price, Dosage and Clinical Trial Insight 2025" Report Highlights:
    Global Bone Marrow Transplant Market Opportunity: US$ 15 Billion
    Cancer Stem Cell Therapy Clinical Pipeline: 37 Therapies
    Majority Stem Cells In Preclinical Phase: 18 Therapies
    Cancer Stem Cell Therapy Clinical Pipeline by Country: More Than 30 In USA
    Cancer incidences are escalating as a result of which demand for better therapeutics is increasing across the globe.
  • Cancer stem cell therapeutics is expected to change this scenario as they act on the very basis of the development of cancer cells.
  • Innovations in the pharmaceutical industry seem to be the main driving force for the development of cancer stem cell therapies.
  • Less number of competitors are expected to increase the profit margins and allow cancer stem cell therapy developers to occupy major market shares.

Stem Cell Banking Market Worth $9.30 Billion by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, June 20, 2019
Branches of biology, Biology, Stem cells, Life sciences, Stem-cell line, HSCT, Hematopoietic stem cell transplantation, Hematopoietic stem cell, Amniotic stem cell bank, Stem-cell therapy, Stem cell controversy

The market is projected to reach USD 9.30 Billion by 2023 from USD 6.28 Billion in 2018, at a CAGR of 8.2%

Key Points: 
  • The market is projected to reach USD 9.30 Billion by 2023 from USD 6.28 Billion in 2018, at a CAGR of 8.2%
    Factors such as increase in hematopoietic stem cell transplantation (HSCT) procedures, increasing investments in stem cell-based research, and growing awareness on the therapeutic potential of stem cells are driving the growth of the Stem Cell Banking Market.
  • Based on source, the Stem Cell Banking Market is segmented into placental, bone marrow-derived, adipose tissue-derived, human embryo-derived, dental pulp, and other stem cell sources.
  • By application, the Stem Cell Banking Market is segmented into personalized banking, clinical, and research applications.
  • The expanding network of stem cell banking services, ongoing approval of stem cell lines for various disease treatment, recent technological advancements in the field of stem cell collection and preservation techniques, rising public-private investments for stem cell researches, growing number of stem cell transplantation procedures, and increasing public preference for private stem cell banking over public stem cell banks are driving the growth of the Stem Cell Banking Market in North America.

Stem Cell Banking Market Worth $9.30 Billion by 2023 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, June 20, 2019
Branches of biology, Biology, Stem cells, Life sciences, Stem-cell line, HSCT, Hematopoietic stem cell transplantation, Hematopoietic stem cell, Amniotic stem cell bank, Stem-cell therapy, Stem cell controversy

The market is projected to reach USD 9.30 Billion by 2023 from USD 6.28 Billion in 2018, at a CAGR of 8.2%

Key Points: 
  • The market is projected to reach USD 9.30 Billion by 2023 from USD 6.28 Billion in 2018, at a CAGR of 8.2%
    Factors such as increase in hematopoietic stem cell transplantation (HSCT) procedures, increasing investments in stem cell-based research, and growing awareness on the therapeutic potential of stem cells are driving the growth of the Stem Cell Banking Market.
  • Based on source, the Stem Cell Banking Market is segmented into placental, bone marrow-derived, adipose tissue-derived, human embryo-derived, dental pulp, and other stem cell sources.
  • By application, the Stem Cell Banking Market is segmented into personalized banking, clinical, and research applications.
  • The expanding network of stem cell banking services, ongoing approval of stem cell lines for various disease treatment, recent technological advancements in the field of stem cell collection and preservation techniques, rising public-private investments for stem cell researches, growing number of stem cell transplantation procedures, and increasing public preference for private stem cell banking over public stem cell banks are driving the growth of the Stem Cell Banking Market in North America.